Objective: To estimate the cost-effectiveness of once-daily tenofovir/ emtricitabine compared with twice-daily zidovudine/lamivudine and once-daily abacavir/lamivudine in treatment-naïve adults with HIV-1 infection in the United States. Methods: A Markov model with four therapy lines and six health states based on CD4 ϩ cell-count ranges was developed to estimate lifetime costs and health outcomes. Efficacy data (virologic response and CD4 ϩ cell-count changes) for first-line therapy were from 144-week results of Study 934 comparing tenofovir/ emtricitabine with zidovudine/lamivudine and 48-week results of Study CNA30024 comparing abacavir/lamivudine with zidovudine/ lamivudine, all in combination with efavirenz. Data from Study CNA30024 for abacavir/lamivudine were adjusted to allow for an indirect comparison with tenofovir/emtricitabine. Subsequent therapy lines were based on likely baskets of antiretroviral therapy recommended by US treatment guidelines. Utility values, mortality rates, and costs (2009 US dollars) were obtained from published sources. Basecase results were tested in sensitivity and variability analyses. Results: Average discounted results showed that individuals using tenofovir/emtricitabine were predicted to remain on first-line therapy for 7.7 years, accrue lifetime costs of $747,327, and experience 15.75 quality-adjusted life-years (QALYs), compared with 6.0 years, $777,090, and 15.68 QALYs for individuals using abacavir/lamivudine and 5.8 years, $778,287, and 15.44 QALYs for individuals using zidovudine/ lamivudine. Tenofovir/emtricitabine was cost-effective compared with the other two first-line regimens in more than 75% of all probabilistic sensitivity analysis simulation runs for every willingness-to-pay threshold between $0 and $250,000 per QALY gained. Results were robust in variability and one-way sensitivity analyses. Conclusions: Tenofovir/emtricitabine was predicted to be more effective and cost-saving compared with abacavir/lamivudine and zidovudine/lamivudine in treatment-naïve adults with HIV-1 infection in the United States.
Introduction
Major therapeutic advances in the 15 years since the introduction of highly active antiretroviral therapy (HAART) have led to a reduction in morbidity and mortality specifically due to acquired immune deficiency syndrome (AIDS) [1] [2] [3] [4] [5] and an increase in life expectancy (37.3 years postinfection) for individuals with human immunodeficiency virus (HIV) infection [6] . Rising antiretroviral drug costs and longer life expectancies have led to higher lifetime treatment costs, increasing from $94,000 in 1992 [7] to over $600,000 in 2004 [8] . Therefore, costs of antiretroviral regimens have become important considerations in addition to efficacy and safety.
First-line therapy plays a significant role in each individual's long-term health outcomes and total health care costs. Durable suppression of plasma HIV ribonucleic acid (RNA) inhibits disease progression and reduces disease-related morbidity and mortality [9] . First-line therapy currently represents each individual's best chance at durable viral suppression because resistance is low and adherence to relatively tolerable and simple regimens (i.e., regimens with low pill burden and daily dosing) is likely to be high [10 -12] . The choice of initial therapy is important because shortterm outcomes (i.e., viral suppression, side effects, and development of resistance) may affect an individual's duration on firstline therapy [13] and thus progression through subsequent lines of therapy. Delaying more complex and expensive therapy regimens represents an additional benefit potentially conferred by longer first-line treatment durations.
For treatment-naïve individuals with HIV-1 infection, United States (US) treatment guidelines recommend using the nucleotide/ nucleoside reverse transcriptase inhibitor (NRTI) fixed-dose combination tenofovir DF/emtricitabine (TDF/FTC) with the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV), one of two protease inhibitors (PI) boosted with low-dose ritonavir (/r), or the integrase strand transfer inhibitor raltegravir [9] . The fixed-dose combinations abacavir/lamivudine (ABC/3TC) and zidovudine/lamivudine (ZDV/3TC) are listed as alternative NRTI pairs.
Studies testing EFV-based regimens in treatment-naïve individuals have shown that more individuals receiving TDF/FTC ex-perienced virologic response than individuals receiving other NRTI pairs [14] , including ZDV/3TC [15] [16] [17] and ABC/3TC [18 -21] . Additionally, a recent meta-analysis found that TDF/FTC was more effective than ABC/3TC when used with a boosted PI as a first-line regimen [22] . For treatment-naïve individuals overall, NNRTI-based regimens have been associated with better efficacy [13, [23] [24] [25] [26] and longer average treatment duration [13, 27] than PIbased regimens.
This study evaluates the cost-effectiveness of once-daily TDF/ FTC compared with twice-daily ZDV/3TC and once-daily ABC/3TC, each used in combination with EFV in treatment-naïve adults with HIV-1 infection in the US, to highlight the potential effects of the choice of first-line NRTI pair on long-term costs and health outcomes.
Methods

Model overview
A Markov model with a 1-year cycle period was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA) to follow a population of treatment-naïve HIV-positive individuals as they progressed through first-line, second-line, third-line, and non-suppressive therapy (Fig. 1 ). Costs and health outcomes were calculated for each of three first-line HAART regimens being compared: TDF/FTC, ABC/3TC, and ZDV/3TC, each used in combination with EFV (referred to hereafter by NRTI pair).
Using clinical trial data at various time points, the model tracked the percentage of individuals in each arm who remained on first-line therapy and who had HIV-1 RNA less than 400 copies/ mL. Those individuals who dropped out of this group for any reason, including adverse events, lack of initial virologic response, or loss of initial virologic response, switched from first-line to second-line therapy. A threshold viral load of 400 copies/mL was chosen as a clinically relevant point above which individuals would likely switch to a new regimen. Individuals entered the model in one of six possible Markovmodel health states defined by CD4 ϩ cell-count ranges (Ͼ 500, 351-500, 201-350, 101-200, 51-100, and 0 -50 cells/L). Every year, individuals remained in their current health state or moved to another state of the model, where transition probabilities were estimated from clinical trial and observational cohort data. There was a chance of death from any therapy line, HIV-1 RNA level, or CD4 ϩ cell-count range.
The model was developed to focus on different first-line regimens from the NRTI drug class when combined with EFV. First-line therapies were modeled using clinical trial data. As individuals switched to later lines of therapy, costs and efficacy were based on a basket of regimens recommended by the US treatment guidelines [9] .
The analysis took a US societal perspective. Incremental costeffectiveness ratios included direct medical costs in the numerator and either life-years or quality-adjusted life years (QALYs) in the denominator. As recommended for health economic analyses, indirect costs, including those associated with productivity losses, were assumed to be captured in the QALY estimates [28] .
Input parameters
Population characteristics and efficacy data for first-line regimens
A MEDLINE search and a review of scientific conference abstracts for clinical trials comparing the model's first-line regimens headto-head identified four studies: Study 934 [15] [16] [17] , Study CNA30024 [29] , the ACTG 5202 study [18 -19] , and the ASSERT study [20 -21] . None of these studies included all three first-line regimens. Study 934 and Study CNA30024 had comparable virologic efficacy endpoints (time to regimen failure) for all three first-line regimens, allowing for an indirect comparison of TDF/FTC and ABC/3TC. The ACTG 5202 study was excluded because full results with comparable endpoints have not been published; the ASSERT study was excluded because the unusually high drop-out rate confounded the efficacy results.
Characteristics of the modeled population, including baseline gender (86.5% male), mean age (38 years), and CD4 ϩ cell-count distribution (Appendix S1 found at doi:10.1016/j.jval.2011.01.009), were assumed to be equivalent to those of the modified intent-totreat population in Study 934, a head-to-head clinical trial comparing TDF/FTC and ZDV/3TC each in combination with EFV in treatmentnaïve HIV-1-infected individuals [15] [16] [17] . Baseline characteristics available from study CNA30024, which compared ABC with ZDV each used in combination with 3TC and EFV, were similar.
Clinical efficacy and safety data for the TDF/FTC plus EFV arm and the ZDV/3TC plus EFV arm of the model were derived from the 144-week results of Study 934 [15] [16] [17] . Efficacy and safety data for the ABC/3TC plus EFV arm of the model were estimated from the 48-week results of Study CNA30024 [29] . These two trials both included ZDV/3TC plus EFV, which allowed for a direct comparison between TDF/FTC and ZDV/3TC and an indirect comparison between TDF/FTC and ABC/3TC. To make the indirect comparison, efficacy parameters (virologic response and CD4
ϩ cell-count changes) for ABC/3TC were estimated by applying the relative difference between the ABC/3TC arm and the ZDV/3TC arm of Study CNA30024 to the The proportion of clinical trial participants remaining on firstline therapy with HIV-1 RNA less than 400 copies/mL at various time points was used to determine the proportion of individuals remaining on first-line therapy during each of the first 3 years of the model. Beyond year 3, the model extrapolated data from baseline through week 144, using an exponential function to estimate an annual probability of switching from first line ( Table 1) .
Immunologic response, measured by annual increase in CD4 ϩ cell count, was used to estimate the transition probabilities between the CD4 ϩ cell-count health states of the model. Specifically, transition probabilities were calculated from the means and standard deviations of the CD4 ϩ cell-count increases observed at 48, 96, and 144 weeks in Study 934 and from the mean increase observed at 48 weeks in Study CNA30024. After week 144 (year 3), the model allowed for a modest continued increase in CD4 ϩ cell count for those individuals still on first-line therapy ( 
Efficacy data for post-first-line regimens
In subsequent therapy lines, individuals received treatment according to US treatment guidelines [9] and current clinical practice. Individuals received a PI-based regimen as second-line therapy and raltegravir, etravirine, darunavir/r, and two NRTIs as third-line therapy. For non-suppressive therapy, the model assumed individuals would remain on a drug regimen equal in cost to their third-line regimen, despite the initiation of treatment failure. While on each post-first-line regimen in the model, individuals experienced an average annual change in CD4 ϩ cell count based on studies of HIVinfected individuals at different stages of disease (Table 2 ) [30 -33] . abacavir/lamivudine. † For third-line therapy, the average was estimated using the CD4 ϩ cell-count increase from baseline to 48 weeks (108 cells) and assuming the CD4 ϩ cell-count increase observed between 24 and 48 weeks (9 cells), continued for the remaining time on therapy [31] [32] . The total increase then was divided by the median time on therapy [27] .
In each year of the model, a certain percentage of individuals in each therapy line switched to the next therapy line. The annual probabilities of switching were calculated from the median time on each therapy line as observed in a recent United Kingdom cohort study by Beck and colleagues [27] . Individuals on non-suppressive therapy were assumed to remain on non-suppressive therapy until death (Table 2) .
Cost data
First-line annual antiretroviral drug costs for TDF/FTC, ABC/3TC, and ZDV/3TC, each in combination with EFV, were $16,819, $16,391, and $15,621, respectively. For each subsequent therapy line, average annual antiretroviral drug costs were estimated based on the HAART regimens used (Table 2) . Drug costs were taken from the wholesale acquisition cost from the Red Book [34] for the indicated daily dose for each antiretroviral drug.
Individuals in each CD4 ϩ cell-count range in the model incurred costs while in that health state. Annual non-antiretroviral medical and medication costs by CD4
ϩ cell-count range were derived from a US study by Gebo and colleagues [35] , which estimated inpatient, outpatient, and emergency department utilization and costs through interviews with HIV-infected participants (Table 3) .
Lastly, resource use (additional laboratory tests, a resistance assay, and a clinician visit) for switching therapy line was based on clinical expert opinion, and the cost ($829 per switch) [36] was assumed the same for each switch.
All costs were inflated to 2009 US dollars, when necessary, using the medical care component of the consumer price index [37] .
Utility and mortality data
In each CD4
ϩ cell-count range, individuals were assumed to experience different levels of quality of life, quantified by different utility weights. Utility weights taken from community-based preferences [38] were mapped to the model health states as follows: AIDS (CD4 ϩ range 0 -50), symptomatic HIV-1 infection (CD4 ϩ range 50 -350), and asymptomatic HIV-1 infection (CD4 ϩ range Ͼ 350) ( Table 3) .
Mortality was modeled using an annual probability of death due to causes related or unrelated to AIDS. For AIDS-related causes, the model used mortality rates by CD4
ϩ cell-count range [1] and converted these rates to probabilities ( Table 3 ). The probability of death from non-AIDS-related causes was based, in part, on age-and gender-specific 2006 US general population mortality data [39] , weighted by the percentage of males and females in the modeled population. Individuals entered the model at age 38; an annual adjustment factor, estimated by fitting an exponential curve to age-specific mortality data, was applied to account for aging. A relative risk value of 2.5 [40] was applied to the general population mortality data, to account for higher non-AIDSrelated mortality rates observed among individuals with HIV-1 than in the general population. This relative-risk value does not include AIDS-related deaths but captures other causes of elevated death rates among individuals with HIV, such as drug overdose, hepatitis co-infection, or cardiovascular disease [4 -5] , which is now known to be associated with HIV-1 itself and some antiretroviral therapies.
Adverse events
Adverse events (anemia, lipoatrophy, myocardial infarction) that impact significantly different proportions of individuals between arms of the model were modeled explicitly to capture the (differential) effects on costs, quality of life, and adherence. In addition, the model included the one-time cost for the HLA-B*5701 screening test for individuals in the ABC/3TC arm of the model and annual renal monitoring costs for individuals in the TDF/FTC arm of the model [41] [42] [43] [44] [45] (Table 4) .
Model outcomes
The model estimated total direct medical costs, including antiretroviral drugs costs, costs for adverse events, other medical costs (including costs for disease monitoring, switching therapy lines, treating opportunistic and other infections and adverse events other than those explicitly modeled), and non-antiretroviral drug costs. Health outcomes included life-years, QALYs, years on firstline therapy, percentages of deaths due to AIDS-related causes, and percentages of people remaining on first-line therapy (for time horizons shorter than remaining lifetime only). Incremental costeffectiveness ratios included the incremental cost per life-year gained and per QALY gained. As recommended for US cost-effectiveness analyses, all costs and outcomes were discounted at a 3% annual rate [28] .
Uncertainty and variability analyses
In addition to the base-case analysis, extensive analyses were performed to evaluate the impact of parameter uncertainty on the model results. One-way sensitivity analysis was performed using realistic ranges for each parameter derived from published sources to the extent possible (Appendix S1). Probabilistic sensitivity analysis was performed by simultaneously sampling all input parameters from appropriate probability distributions in 10,000 Monte Carlo simulations (Appendix S1). In addition, variability analysis was conducted to test the impact of modeling assumptions, including the model time horizon, discount rate, and incidence and cost of adverse events. 
Results
Base-case results
The model estimated that TDF/FTC had the lowest discounted lifetime costs ($747,327) compared with either ABC/3TC ($777,090) or ZDV/3TC ($778,287) ( Table 5 ). Antiretroviral drugs represented approximately 65% of lifetime costs for all arms. The model estimated that TDF/FTC resulted in more life-years and QALYs compared with either ABC/3TC or ZDV/3TC. Therefore, TDF/FTC was the dominant first-line treatment option, exhibiting lower costs and more QALYs compared with both ABC/3TC and ZDV/3TC.
Uncertainty analysis results
One-way sensitivity analysis demonstrated that the model results were most sensitive to efficacy parameters for the first-line regimens (virologic response, CD4 ϩ cell-count increases), annual change in CD4 ϩ cell count in later therapy lines, and antiretroviral drug costs in later therapy lines. For the pair-wise comparison between TDF/FTC and ZDV/3TC, TDF/FTC remained the dominant treatment strategy (i.e., exhibited lower costs and better health outcomes) for all ranges tested in the one-way sensitivity analysis. TDF/FTC remained dominant compared with ABC/3TC for all ranges tested, with the exception of instances in which the sensitivity analysis examined CD4 ϩ cell-count increases that were higher for ABC/3TC than for TDF/FTC. In these cases, ABC/3TC exhibited higher costs and more QALYs than TDF/FTC, but the incremental cost-effectiveness ratio of ABC/3TC versus TDF/FTC remained above $96,000 per QALY gained.
Probabilistic sensitivity analysis revealed that TDF/FTC was cost-effective compared with ABC/3TC and ZDV/3TC in more than 75% of all simulation runs for every willingness-to-pay threshold between $0 and $250,000 per QALY gained (Fig. 2) . Specifically, at a willingness to pay of $50,000 per QALY gained, TDF/FTC was predicted to be cost-effective 88.1% of the time, compared with 7.8% for ABC/3TC and 4.1% for ZDV/3TC.
Variability analysis results
Short-term model results found that, compared with the other two first-line regimens, a larger percentage of individuals remained on TDF/FTC at 5 years (19%-23% more). Undiscounted lifetime results revealed that individuals initiating therapy with TDF/FTC remained on first-line therapy 2.4 and 2.7 years longer than individuals initiating therapy with ABC/3TC or ZDV/3TC, respectively. The incremental results of the model were consistent for different time horizons and discount rates, with TDF/FTC being the dominant first-line treatment strategy in most cases. Conclusions of the model also did not change when myocardial infarction rates were set equal to zero for all arms (Table 5) . Additional scenarios testing a rate of 5% for hypersensitivity reaction instead of HLA-B*5701 screening for the ABC/3TC arm or a rate of 2% for renal toxicity for the TDF/FTC arm showed that TDF/FTC remained the dominant treatment strategy (results not shown).
Discussion
This analysis demonstrates that initiating HAART with TDF/FTC plus EFV (the components of Atripla) resulted in lower lifetime costs and more years on first-line therapy, life-years, and QALYs, compared with either ABC/3TC plus EFV or ZDV/3TC plus EFV as a first-line regimen in treatment-naïve adults with HIV-1 infection. Model results were driven by better virologic response in the TDF/ FTC arm, which allowed more individuals to delay higher-cost, later-line therapy and eventual disease progression.
In general, sensitivity analysis found that the results of the model were robust. Probabilistic sensitivity analysis showed that TDF/FTC was cost-effective, compared with ABC/3TC and ZDV/ 3TC, the large majority of the time (Ͼ 75%) over a wide range of willingness-to-pay thresholds. The model was sensitive to the clinical data (particularly for the comparison between TDF/FTC and ABC/3TC), indicating the importance of including head-tohead data for these two regimens. Nevertheless, the cost-effectiveness results supported the US clinical treatment guidelines, which recommend TDF/FTC as the preferred NRTI pair for treatment-naïve individuals [9] .
To our knowledge, there is only one other US study comparing NNRTI-based regimens in treatment-naïve individuals: Schackman and colleagues [46] found that initiating HAART with ABC/ 3TC and the HLA-B*5701 screening test was cost-effective if ABC/ 3TC had efficacy equal to TDF/FTC. Our study, which attempted to model the difference in efficacy between ABC/3TC and TDF/FTC via an indirect comparison using data from two head-to-head clinical trials, found that TDF/FTC dominated ABC/3TC in the basecase analysis. However, the results of both our model and the Schackman model are sensitive to assumptions about efficacy, [29] . † Incidence of lipoatrophy for ABC/3TC was assumed equal to that observed in the tenofovir arm of the ACTG 5142 metabolic substudy [24] .
emphasizing again the importance of utilizing head-to-head data when available. For any model, it is important to compare clinically relevant outcomes of the model with observational studies, to validate how well the model matches real-world data. Cohort studies have reported increases in life expectancy over time and have found that life expectancy varies widely, depending on the year in which HAART was initiated, age, gender, history of injection drug use, and baseline viral load and CD4 ϩ cell count [4, 6, [47] [48] [8, 49, 50] . Our model also predicted that for HIVinfected individuals initiating HAART in the US today (i.e., in 2011), approximately 21% would die of AIDS-related causes. As expected, this result is lower than the percentages found in US observational studies (25%-56%) [2] [3] [4] [5] because our model included new, highly efficacious drugs. These results corroborate recent evidence that as new HIV-1 treatment regimens are introduced, the risk of death from AIDS-related causes may continue to decrease and life expectancy may continue to increase.
One of the strong points of our model is that the comparison of TDF/FTC and ZDV/3TC is based on head-to-head clinical trial data collected over a follow-up period of nearly 3 years. The availability of 144-week data improves the reliability of long-term efficacy estimates extrapolated for these two HAART regimens after 144 weeks. In addition, we explicitly modeled adverse events that were significantly different between the three first-line comparator regimens. Interestingly, our model showed that the cost of treating adverse events for all three regimens was relatively small compared with lifetime costs (Ͻ 1%). Thus, while safety profiles of HAART regimens are clinically important, adverse events had a limited impact on the model's economic outcomes, mostly due to relatively low treatment costs compared with antiretroviral drug costs.
Our analysis has several limitations that should be well understood in interpreting the results. First, the results of this analysis are restricted to first-line, EFV-based HAART regimens with brand pricing and full regimen switches upon therapy failure. The analysis did not consider other NNRTIs (e.g., nevirapine for pregnant women), third agents from other drug classes, generic drug pricing, or drug substitutions within regimens. This approach was chosen as a first iteration of the model in order to help inform clinicians about the cost-effectiveness of first-line, EFV-based regimens. A more complex analysis would be necessary to model and to evaluate the cost-effectiveness of all possible first-line therapy options.
Also, recent results of the ACTG 5202 trial reported that TDF/ FTC was significantly more efficacious compared with ABC/3TC among individuals with high baseline viral loads (Ն 100,000 copies/mL) but not among individuals with low baseline viral loads. Therefore, the results of our analysis, which included better virologic efficacy for TDF/FTC overall, may be most applicable to individuals who initiate therapy with high viral loads [18 -19] .
Finally, an indirect comparison between TDF/FTC and ABC/3TC was necessary in the absence of head-to-head clinical trial data. However, Study 934 and Study CNA30024 reported remarkably similar results for ZDV/3TC in combination with EFV. Thus, efficacy data for ABC/3TC from Study CNA30024 required only a small (upward) adjustment, which was conservative relative to TDF/ FTC. Clinical trials comparing TDF/FTC and ABC/3TC, both with EFV, in treatment-naïve individuals are currently ongoing [18 -21] . Results from the ACTG 5202 trial showed that, among the subgroup of participants receiving EFV, more participants receiving TDF/FTC (89.8%) than ABC/3TC (85.3%) remained free of virologic failure at 96 weeks [19] . Once full results of the ACTG 5202 trial are published (specifically time to regimen failure), our model's comparison of TDF/FTC with ABC/3TC will be more reliable.
This study revealed that among those initiating HAART with EFV-based regimens, individuals using TDF/FTC may have lower costs and better short-and long-term health outcomes, compared with individuals using either ABC/3TC or ZDV/3TC. More individuals with durable viral suppression yielded better clinical outcomes and cost savings, due to the postponement of more expensive subsequent lines of therapy and lower costs associated with disease-related resource use.
